Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer biology: signatures guide drug choice.

× No keyword cloud information.

24 in total

Review 1. mTOR and other effector kinase signals that impact T cell function and activity.

Authors: Darienne R Myers; Benjamin Wheeler; Jeroen P Roose
Journal: Immunol Rev Date: 2019-09 Impact factor: 12.988

2. Regulation of the Small GTPase Ras and Its Relevance to Human Disease.

Authors: Kayla R Kulhanek; Jeroen P Roose; Ignacio Rubio
Journal: Methods Mol Biol Date: 2021

3. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Authors: Marsilius Mues; Laila Karra; Damia Romero-Moya; Anica Wandler; Matthew J Hangauer; Olga Ksionda; Yvonne Thus; Marthe Lindenbergh; Kevin Shannon; Michael T McManus; Jeroen P Roose
Journal: Cell Rep Date: 2019-04-09 Impact factor: 9.423

4. Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle.

Authors: Marsilius Mues; Jeroen P Roose
Journal: Small GTPases Date: 2016-05-09

5. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.

Authors: Nader N El-Chaar; Stephen R Piccolo; Kenneth M Boucher; Adam L Cohen; Jeffrey T Chang; Philip J Moos; Andrea H Bild
Journal: Mol Oncol Date: 2014-05-20 Impact factor: 6.603

6. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

Authors: Catherine Hartzell; Olga Ksionda; Ed Lemmens; Kristen Coakley; Ming Yang; Monique Dail; Richard C Harvey; Christopher Govern; Jeroen Bakker; Tineke L Lenstra; Kristin Ammon; Anne Boeter; Stuart S Winter; Mignon Loh; Kevin Shannon; Arup K Chakraborty; Matthias Wabl; Jeroen P Roose
Journal: Sci Signal Date: 2013-03-26 Impact factor: 8.192

Cancer biology: signatures guide drug choice.

Review 1. mTOR and other effector kinase signals that impact T cell function and activity.

2. Regulation of the Small GTPase Ras and Its Relevance to Human Disease.

3. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

4. Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle.

5. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.

6. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

7. Simpler evaluation of predictions and signature stability for gene expression data.

8. Signal pathways in ouabain-induced proliferation of leukemia cells.

Review 9. Molecular markers in colorectal cancer: genetic bases for a customised treatment.

Review 10. The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers.